BioCorRx Inc. (BICX)
|Net Income (ttm)||-3.77M|
|Trading Day||February 23|
|Day's Range||0.00 - 0.00|
|52-Week Range||0.16 - 3.12|
BioCorRx Announces Update on NIDA Grant and Development of Naltrexone Implant for the Treatment of Opioid and Alcohol Use Disorders
ANAHEIM, CA, Jan. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx, through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States. It distributes and licenses BioCorRx recovery program, a medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant. The company is also developing BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. It distributes its program to heal... [Read more...]
Medical Care Facilities
|Stock Exchange |
|Ticker Symbol |
In 2019, BioCorRx's revenue was $240,259, a decrease of -36.21% compared to the previous year's $376,656. Losses were -$6.04 million, -7.25% less than in 2018.